Kikwit Ebola Virus Disease Progression in the Rhesus Monkey Animal Model
Richard S. Bennett, James Logue, David X. Liu, Rebecca Reeder, Krisztina Janosko, Donna L. Perry, Timothy K. Cooper, Russell Byrum, Danny Ragland, Marisa St. Claire, Ricky Adams, Tracey Burdette, Tyler Brady, Kyra Hadley, Mary‐Jo Waters, Rebecca Shim, William E. Dowling, Jing Qin, Ian Crozier, Peter B. Jahrling, Lisa E. Hensley
Abstract
Ongoing Ebola virus disease outbreaks in the Democratic Republic of the Congo follow the largest recorded outbreak in Western Africa (2013-2016). To combat outbreaks, testing of medical countermeasures (therapeutics or vaccines) requires a well-defined, reproducible, animal model. Here we present Ebola virus disease kinetics in 24 Chinese-origin rhesus monkeys exposed intramuscularly to a highly characterized, commercially available Kikwit Ebola virus Filovirus Animal Non-Clinical Group (FANG) stock. Until reaching predetermined clinical disease endpoint criteria, six animals underwent anesthesia for repeated clinical sampling and were compared to six that did not. Groups of three animals were euthanized and necropsied on days 3, 4, 5, and 6 post-exposure, respectively. In addition, three uninfected animals served as controls. Here, we present detailed characterization of clinical and laboratory disease kinetics and complete blood counts, serum chemistries, Ebola virus titers, and disease kinetics for future medical countermeasure (MCM) study design and control data. We measured no statistical difference in hematology, chemistry values, or time to clinical endpoint in animals that were anesthetized for clinical sampling during the acute disease compared to those that were not.